ARS Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by neffy Nasal Spray Adoption
ARS Pharmaceuticals (SPRY) reported third-quarter 2026 total revenue of $37.7 million, an increase from $32.5 million in the same period last year. This growth was primarily driven by its neffy nasal spray, which saw U.S. net product revenue rise to $33.4 million and end-user demand surge by 42%. The company successfully expanded its total U.S. market share to 5%, with field-targeted market share reaching 9% due to aggressive commercial execution. Despite the revenue growth, the company reported a net loss of $35.6 million ($0.36 per share), though this represents an improvement over the $51.2 million loss in Q3 2025. Management is focused on achieving cash flow breakeven by the end of 2027 through disciplined SG&A expense management and expanding its pipeline into the chronic spontaneous urticaria (CSU) market, with Phase 2b data for ARS-2 expected in early 2027.
Tickers: $AAPL $AMZN $GOOG $META $MSFT $NVDA $SPRY $TSLA
Topics: Market Share Nasal Spray Adoption Net Loss Reduction Revenue Growth
Read the full article at Motley Fool
Part of the story AerSale Reports Q3 2026 Revenue Growth Amid Net Loss Driven by Goodwill Impairment (9 articles)